Shiu Jennifer R, Forgie Sarah E D, Pinsk Maury, Romanick Marcel
Regional Pharmacy Services, Stollery Children's Hospital, Alberta Health Services, Edmonton, Alberta, Canada.
J Pediatr Hematol Oncol. 2012 May;34(4):e155-7. doi: 10.1097/MPH.0b013e3182300254.
Although case reports of hyperphosphatemia have been previously described in patients receiving liposomal amphotericin B, this has not been reported in patients receiving the lipid complex formulation. We report a case of hyperphosphatemia that persisted despite switching from liposomal to lipid complex amphotericin B in a child with invasive zygomycosis. This case suggests that in the context of acute renal dysfunction, hyperphosphatemia may also be observed with lipid complex amphotericin B. This case highlights the importance of differentiating between pseudohyperphosphatemia and hyperphosphatemia to prevent complications.
尽管先前已有接受脂质体两性霉素B治疗的患者出现高磷血症的病例报告,但接受脂质复合物制剂治疗的患者中尚未有此类报告。我们报告了1例侵袭性接合菌病患儿,尽管从脂质体两性霉素B换用脂质复合物两性霉素B治疗,高磷血症仍持续存在。该病例提示,在急性肾功能不全的情况下,脂质复合物两性霉素B治疗也可能出现高磷血症。该病例强调了区分假性高磷血症和高磷血症以预防并发症的重要性。